Skip to main content

Stem Cells

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
Stemchymal®Phase 11 trial
Active Trials
NCT03629015Withdrawn0Est. May 2020
Steminent Biotherapeutics
1 program
1
Stemchymal®Phase 1
Arthrex
ArthrexCA - Santa Barbara
1 program
Filgrastim InjectionPHASE_11 trial
Active Trials
NCT03381599Completed10Est. Sep 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BioTherapeutics IncStemchymal®
ArthrexFilgrastim Injection

Clinical Trials (2)

Total enrollment: 10 patients across 2 trials

Safety Study of Stemchymal® in Acute Liver Failure

Start: Oct 2018Est. completion: May 20200
Phase 1Withdrawn
NCT03381599ArthrexFilgrastim Injection

Stem Cells After Peripheral Mobilization and Harvest

Start: Mar 2018Est. completion: Sep 201910 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.